CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Vitamin B12Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug2717 Zinc Citrate Wiki 1.00
drug2664 Vitamin D3 Wiki 0.50
drug2662 Vitamin C Wiki 0.30
drug262 Azithromycin Wiki 0.17
drug1086 Hydroxychloroquine Wiki 0.10

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018450 Disease Progression NIH 0.26

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial: The International ALLIANCE Study

COVID-19 is a global pandemic. So far encouraging results have been shown in different parts of the world with the utilisation of hydroxycloroquine, zinc, and azithromycin, and early studies into some of these, plus some with Vitamin C, have also proven beneficial. Vitamin D levels have also been shown to be an important indicator to the severity of symptoms in COVID-19 patients.

NCT04395768 COVID19 Dietary Supplement: Vitamin C Drug: Hydroxychloroquine Drug: Azithromycin Dietary Supplement: Zinc Citrate Dietary Supplement: Vitamin D3 Dietary Supplement: Vitamin B12
MeSH:Disease Progression

Primary Outcomes

Description: Composite measure: Change in severity and duration of symptoms

Measure: Symptoms

Time: once daily for 15 days since enrollment/baseline at admission to hospital

Description: total number of days in hospital since admission

Measure: Length of hospital stay

Time: at 15 and 45 days since admission/ enrolment

Description: need for invasive mechanical ventilation or mortality within 15 days from enrolment

Measure: invasive mechanical ventilation or mortality

Time: any time within 15 days from enrolment

Secondary Outcomes

Description: Death

Measure: Mortality

Time: 15 and 45 days since enrolment

Description: need for and number of days of invasive mechanical ventilation, in case of no need for mechanical ventilation: days=0

Measure: mechanical ventilation

Time: at 15 and 45 days since enrolment

Description: need for and number of days for humidified high-flow oxygen

Measure: oxygen

Time: 15 and 45 days since enrolment

Description: admission to ICU (intensive care unit)

Measure: ICU

Time: 15 and 45 days since enrolment

Description: days in hospital

Measure: days in hospital

Time: 15 and 45 days since enrolment

Description: days in ICU

Measure: days in ICU

Time: 15 and 45 days since enrolment

Description: need for and days of renal replacement therapy

Measure: renal replacement therapy

Time: 15 and 45 days since enrolment

Description: need for and days of Extracorporeal support

Measure: Extracorporeal support

Time: 15 and 45 days since enrolment

No related HPO nodes (Using clinical trials)